NASDAQ:GRNA GreenLight Biosciences (GRNA) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free GRNA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.30▼$0.3050-Day Range$0.30▼$0.3052-Week Range$0.18▼$5.90Volume732 shsAverage Volume486,986 shsMarket Capitalization$45.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get GreenLight Biosciences alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About GreenLight Biosciences Stock (NASDAQ:GRNA)FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.Read More Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. GRNA Stock News HeadlinesApril 21, 2024 | washingtonpost.comGreenlight Coupon CodesDecember 20, 2023 | bbc.comSplashdown Quaywest gets green light for £3m upgradeMay 12, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).September 28, 2023 | bbc.comBroadwalk Shopping Centre redevelopment given green lightSeptember 19, 2023 | forbes.comGreenlight Family Cash Card 2023 ReviewJuly 24, 2023 | finanznachrichten.deGreenLight Biosciences: GreenLight Announces Completion of Merger with Fall Line Endurance FundJuly 24, 2023 | finance.yahoo.comGreenLight Announces Completion of Merger with Fall Line Endurance FundJuly 20, 2023 | finance.yahoo.comGreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding SharesMay 12, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).June 13, 2023 | bizjournals.comRNA company to lay off 96 employees in LexingtonJune 5, 2023 | benzinga.comGRNA ALERT: Levi & Korsinsky, LLP Announces an Investigation of Greenlight BiosciencesJune 1, 2023 | bizjournals.comRTP biotech went public a year ago. Now, it's being acquiredJune 1, 2023 | bizjournals.comThe Petri Dish: GreenLight to go private; C4 licenses cancer drug for $392MMay 31, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating GreenLight Biosciences Holdings BuyoutMay 30, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether GreenLight Biosciences Holdings, PBC has obtained a Fair Price in its transaction with Fall LineMay 30, 2023 | msn.comGreenLight Biosciences trades 36% higher on merger agreement with Fall Line Endurance FundMay 30, 2023 | finance.yahoo.comGreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private TransactionMay 12, 2023 | msn.comRecap: GreenLight Biosciences Q1 EarningsMay 12, 2023 | msn.comGreenLight Biosciences GAAP EPS of -$0.19 beats by $0.08, revenue of $3.82M beats by $3.32MMay 11, 2023 | finance.yahoo.comGreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressApril 12, 2023 | finance.yahoo.comGreenLight Biosciences Releases Inaugural Sustainability ReportApril 1, 2023 | seekingalpha.comGreenLight Biosciences draws private equity interest; up 10%March 30, 2023 | finance.yahoo.comGreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall LineMarch 28, 2023 | finance.yahoo.comGreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial ResultsMarch 9, 2023 | finance.yahoo.comGreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D DayMarch 7, 2023 | finance.yahoo.comGreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D DayMarch 4, 2023 | bbc.co.ukGreenlight Screenwriting LabSee More Headlines Receive GRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GreenLight Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GRNA CUSIPN/A CIK1822691 Webwww.eiacorp.com Phone(760) 809-8079FaxN/AEmployees280Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167,050,000.00 Net Margins-1,521.00% Pretax Margin-1,510.44% Return on Equity-374.26% Return on Assets-122.78% Debt Debt-to-Equity Ratio0.49 Current Ratio1.21 Quick Ratio1.21 Sales & Book Value Annual Sales$10.20 million Price / Sales4.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book0.94Miscellaneous Outstanding Shares151,681,000Free Float105,722,000Market Cap$45.43 million OptionableNot Optionable Beta1.44 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesEthan ZachadnykPresident, CEO, CFO & DirectorKey CompetitorsIN8bioNASDAQ:INABCyclo TherapeuticsNASDAQ:CYTHDyadic InternationalNASDAQ:DYAIOKYO PharmaNASDAQ:OKYOQuince TherapeuticsNASDAQ:QNCXView All Competitors This page (NASDAQ:GRNA) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCollapse of the Petrodollar Colonial Metals[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GreenLight Biosciences Holdings Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.